Last updated: February 15, 2026
Overview of NDC 66993-0078
NDC 66993-0078 refers to a hepatitis C antiviral medication, specifically a formulation of glecaprevir and pibrentasvir. This combination is marketed under the brand name Mavyret by AbbVie. It is approved for a broad range of hepatitis C virus (HCV) genotypes, including genotype 1 through 6.
Market Size and Demand Dynamics
The global hepatitis C market is influenced by the prevalence of HCV infections, typical treatment durations, and pricing policies. As of 2022, approximately 58 million people worldwide are infected with HCV, with significant variances across regions. In the U.S., the Centers for Disease Control and Prevention (CDC) estimates over 2.4 million residents have chronic HCV.
Treatment penetration is increasing, driven by broadening insurance coverage and evolving treatment guidelines. The demand for pan-genotypic drugs like Mavyret is rising due to simplified treatment regimens, which reduces the need for genotype testing.
Competitive Landscape
Mavyret faces competition from other direct-acting antivirals (DAAs):
- Epclusa (Sofosbuvir and Velpatasvir, Gilead): Approved for all genotypes; priced around $74,760 per treatment course.
- Harvoni (Ledipasvir and Sofosbuvir, Gilead): Popular for genotypes 1, 4, 5, 6; initial treatment cost approximately $94,500.
- Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir, Gilead): Used for retreatment; cost around $24,000 for 12 weeks.
Mavyret’s advantages include a shorter 8-week regimen for certain genotypes and a lower wholesale acquisition cost (WAC).
Pricing and Reimbursement
Native pricing in the U.S. is roughly $26,400 per 8-week treatment course, significantly lower than competitors. Public and private payers typically negotiate discounts, with net prices often ranging from $15,000 to $20,000 per course.
In international markets, pricing varies widely. European countries have negotiated prices around €20,000–€30,000 per course, often subsidized by government programs.
Price Trajectories and Market Drivers
The drug's price is influenced by:
- Regulatory decisions: As patent protections last until at least 2030, price erosion from generic entrants is limited for now.
- Patent status and exclusivity: U.S. patent till 2030, potentially extended through patent disputes or secondary patents.
- Market penetration: As treatment guidelines recommend pangenotypic regimens, demand for Mavyret grows, supporting stable pricing.
- Price pressures: Increased use of generic or biosimilar versions post-patent expiry could reduce prices by 50–70% over a decade.
Future Price Projections
- Next 2-3 years: Expect limited change due to patent protections. Prices may slightly decline (5-10%) driven by payer negotiations and institutional discounts.
- 5-7 years: Entry of generic versions predicted. Wholesale prices could fall by 40-60%. Market share of generics could dominate, pushing net prices down sharply.
- Beyond 7 years: Price erosion could stabilize at 70% below current levels, aligning with regional generic pricing trends seen in other DAA drugs.
Market Risks
- Patent challenges: Litigation or patent disputes may accelerate generic entry.
- Regulatory shifts: New guidelines or licensing policies aimed at lowering drug costs could impact pricing.
- Market saturation: Increasing treatment rates may plateau, constraining revenue growth.
Summary Table: Cost Trends and Market Projections
| Timeline |
Price Expectation |
Key Drivers |
| 0-2 years |
Stable to -10% |
Patent protection, ongoing demand |
| 3-5 years |
-20% to -40% |
Negotiated discounts, initial market penetration of generics |
| 5-7 years |
-50% to -60% |
Entry of generics, patent expiry, increased competition |
| 8+ years |
-70% or more |
Widespread generic availability, biosimilar entry |
Conclusion
NDC 66993-0078 (Mavyret) remains a low-cost, high-demand option in the HCV treatment market. Its future pricing will decline primarily once patent protections lapse and generics enter. Short-term prices are projected to stay relatively stable, with a substantial reduction anticipated in five to seven years.
Key Takeaways
- Current U.S. wholesale price: ~$26,400 per 8-week course.
- Market is driven by demand for pan-genotypic, shorter regimens.
- Patent protection extends to at least 2030, limiting immediate generic competition.
- Significant price reductions (up to 70%) expected after patent expiry.
- Pricing in international markets varies by country and subsidy policies.
FAQs
-
What is the current price of NDC 66993-0078 in the U.S.?
Approximately $26,400 for an 8-week treatment course.
-
How does Mavyret compare to competitors in price and efficacy?
Mavyret is priced lower than drugs like Harvoni and Epclusa, with comparable efficacy for broad genotypes and shorter treatment durations.
-
When will generic versions likely enter the market?
Patent expiration is expected around 2030, but legal challenges could accelerate entry.
-
What factors could influence the drug’s future price?
Patent status, market competition, regional regulations, and healthcare policies.
-
How is international pricing different from the U.S.?
Prices are generally lower, negotiated through governmental agencies or other payers, with significant variation across countries.
Citations
[1] Centers for Disease Control and Prevention (CDC). “Hepatitis C Fact Sheet,” 2022.
[2] IQVIA. “Global Market Share Data for HCV Drugs,” 2022.
[3] FDA. “Product Label: Mavyret (glecaprevir/pibrentasvir),” 2017.
[4] GoodRx. “Pricing Data for Hepatitis C Medications,” 2023.
[5] European Medicines Agency. “Market Authorization for Mavyret,” 2019.
